Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Current Deferred Revenue (2022 - 2025)

Historic Current Deferred Revenue for Crinetics Pharmaceuticals (CRNX) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Crinetics Pharmaceuticals' Current Deferred Revenue fell 255.19% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 255.19%. This contributed to the annual value of $2.2 million for FY2024, which is 583.66% up from last year.
  • Crinetics Pharmaceuticals' Current Deferred Revenue amounted to $1.6 million in Q3 2025, which was down 255.19% from $1.9 million recorded in Q2 2025.
  • Over the past 5 years, Crinetics Pharmaceuticals' Current Deferred Revenue peaked at $9.4 million during Q2 2022, and registered a low of $1.6 million during Q3 2025.
  • Moreover, its 4-year median value for Current Deferred Revenue was $6.8 million (2023), whereas its average is $5.1 million.
  • The largest annual percentage gain for Crinetics Pharmaceuticals' Current Deferred Revenue in the last 5 years was 18588.32% (2023), contrasted with its biggest fall of 7535.07% (2023).
  • Over the past 4 years, Crinetics Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $8.3 million in 2022, then crashed by 75.35% to $2.1 million in 2023, then rose by 5.84% to $2.2 million in 2024, then decreased by 24.54% to $1.6 million in 2025.
  • Its Current Deferred Revenue stands at $1.6 million for Q3 2025, versus $1.9 million for Q2 2025 and $2.2 million for Q1 2025.